Increased conc w/ potent (eg, ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, HCV antivirals, HIV PIs) & moderate (eg, erythromycin, diltiazem, verapamil, fluconazole) CYP3A4 inhibitors. Increased risk of myopathy w/ erythromycin, fusidic acid. Increased exposure w/ amiodarone, verapamil. Reduced plasma conc by CYP450 3A inducers eg, efavirenz, rifampin, St. John's wort. Increased systemic exposure w/ ciclosporin. Severe myositis & myoglobinuria w/ fibrates. Increased risk of muscle-related events including rhabdomyolysis w/ ezetimibe. Lowered plasma conc w/ colestipol. Cases of myopathy w/ colchicine. Increased steady-state digoxin conc. Increased plasma conc of norethindrone & ethinyl oestradiol.